ESTRADURIN Drug Patent Profile
✉ Email this page to a colleague
When do Estradurin patents expire, and when can generic versions of Estradurin launch?
Estradurin is a drug marketed by Wyeth Ayerst and is included in one NDA.
The generic ingredient in ESTRADURIN is polyestradiol phosphate. There is one drug master file entry for this compound. Additional details are available on the polyestradiol phosphate profile page.
Summary for ESTRADURIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 6 |
DailyMed Link: | ESTRADURIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ESTRADURIN
US Patents and Regulatory Information for ESTRADURIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wyeth Ayerst | ESTRADURIN | polyestradiol phosphate | INJECTABLE;INJECTION | 010753-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |